Print Friendly, PDF & Email

NCT/Study#

NCT02616965 /

HM-085

A Phase I Trial Assessing The Feasibility Of Romidepsin Combined With Brentuximab Vedotin For Patients With Requiring Systemic Therapy For Cutaneous T-Cell Lymphoma

DISEASE GROUP:
Lymphoma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: